CARB-X is seeking additional accelerators to expand support for its pipeline

Dear All:

It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements said to be imminent.

According to the press release, CARB-X is aiming to partner with additional accelerators in Europe, North America, and the rest of the world to support the Powered by CARB-X portfolio. Up to two accelerators from each of those regions will be selected. The new accelerators will provide a broad range of support to projects funded by CARB-X, address common support needs across projects, and help build the community of people dedicated to fighting drug resistant bacteria.

The new accelerators will be in addition to existing accelerators in the CARB-X network: California Life Sciences Institute (CLSI), RTI International, MassBio, and Wellcome Trust (which is both an accelerator and a funder).

To be considered, accelerator applicants must be a going concern and must be able to work in a fully non-dilutive model. You can find the full Request for Proposals (RFP) here. To apply, click here. And finally, the full press release can be found on line hereApplications are welcome until March 30, 2018.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • [UPDATED with link for 2018 program] 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) 

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top